

Figure 6. The effect of the number of iterations on the accuracy of the proposed algorithm. The figure shows the accuracy of the proposed algorithm as a function of the number of iterations for different values of the parameters α and β . The x-axis represents the number of iterations (from 0 to 100), and the y-axis represents the accuracy (from 0.8 to 1.0). The legend indicates the parameter values: $\alpha = 0.1, \beta = 0.1$ (blue line); $\alpha = 0.1, \beta = 0.2$ (orange line); $\alpha = 0.1, \beta = 0.3$ (green line); $\alpha = 0.1, \beta = 0.4$ (red line); $\alpha = 0.1, \beta = 0.5$ (purple line); $\alpha = 0.1, \beta = 0.6$ (brown line); $\alpha = 0.1, \beta = 0.7$ (pink line); $\alpha = 0.1, \beta = 0.8$ (gray line); $\alpha = 0.1, \beta = 0.9$ (light blue line); $\alpha = 0.1, \beta = 1.0$ (dark blue line).

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the specification:

Please add the following paragraph at page 1, line 3:

--Cross-Reference to Related Applications

This application is a divisional of U.S. Serial No. 09/167,681, filed October 7, 1998. --

In the claims:

Please cancel claims 1-13 and 18-31.

Please add new claims 32-36.

-- 32. The method of claim 14, wherein said sulfotransferase nucleotide sequence variant comprises an adenine at nucleotide 638 of a SULT1A1 nucleic acid sequence.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No EL454377374US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents Washington D.C. 20231

Date of Deposit April 10, 2001

Signature

Vince Defante
Typed or Printed Name of Person Signing Certificate

33. The method of claim 14, wherein said sulfotransferase nucleotide sequence variant encodes a sulfotransferase polypeptide having a histidine at residue 213 of a SULT1A1 polypeptide.

34. The method of claim 15, wherein said sulfotransferase nucleotide sequence variant comprises the SULT1A1*2 allele.

35. The method of claim 34, wherein said method further comprises detecting mutations within one or both of the BRCA1 and BRCA2 genes.

36. The method of claim 14, wherein said sulfotransferase nucleotide sequence variant is detected by allele-specific hybridization, allele-specific restriction digest, mutation-specific polymerase chain reaction, or single-stranded conformational polymorphism detection.--

07039-118002

Applicant : Richard M. Weinshilboum et al.
Serial No. :
Filed :
Page : 3


Attorney's Docket No.: 07039-118002

REMARKS

Applicants have canceled claims 1-13 and 18-31, and added new dependant claims 32-36. Support for these claims can be found, for example, at page 7, lines 5-6 and at page 11, lines 15-24 of the present specification. No new matter has been introduced. Applicants ask that claims 14-17 and 32-36 be examined. No fees are believed to be due. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 4/10/01


Monica McCormick Graham, Ph.D.
Reg. No. 42,600

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

60035398.doc

60035398.doc